Cargando…
A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
BACKGROUND: Nephropathic cystinosis is a rare and severe metabolic disease leading to an accumulation of cystine in lysosomes which especially harms kidney function. A lifelong therapy with the aminothiol cysteamine can delay the development of end-stage renal disease and the necessity of kidney tra...
Autores principales: | van Stein, Christina, Klank, Sabrina, Grüneberg, Marianne, Ottolenghi, Chris, Grebe, Jürgen, Reunert, Janine, Harms, Erik, Marquardt, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438894/ https://www.ncbi.nlm.nih.gov/pubmed/34521447 http://dx.doi.org/10.1186/s13023-021-01991-2 |
Ejemplares similares
-
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023) -
Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
por: Linden, Simone, et al.
Publicado: (2020) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011) -
The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study
por: Bjerre, Anna, et al.
Publicado: (2023)